Ratio Therapeutics expands PharmaLogic manufacturing collaboration for Ac-225RTX-2358 alpha therapy

Ratio Therapeutics has [expanded its manufacturing collaboration](https://www.prnewswire.com/news-releases/ratio-therapeutics-and-pharmalogic-expand-manufacturing-collaboration-to-support-clinical-development-of-ac-225rtx-2358-302785173.html) with radiopharmaceutical CDMO PharmaLogic Holdings Corp., to scale clinical supply of [\[Ac-225\]RTX-2358](https://app.allsci.com/drugs/ASC-DR-0000000044433-1.0-1775585065), its lead FAP-targeted alpha-emitting radioligand therapy currently in the Phase I/II [ATLAS trial](https://app.allsci.com/clinical-trial/ASC-CT-0000001061623-1.0-1760425651) for relapsed or refractory soft tissue sarcoma. The expansion adds PharmaLogic's Idaho Falls therapeutics facility to the manufacturing network and introduces larger-scale multi-dose batch production capabilities. Financial terms were not disclosed. The expanded scope is designed to support ongoing clinical supply for ATLAS and to position the program for potential registrational trials. Ratio, which also operates its own manufacturing facility in Salt Lake City, Utah, is building redundant production infrastructure — a practical necessity for Actinium-225-based therapies, where isotope supply chain complexity and radiolabeling constraints make single-site dependency a material risk. ### Deal context \[Ac-225]RTX-2358 is a small molecule FAP-targeted radiotherapeutic built on Ratio's proprietary Trillium and Macropa platforms. The Trillium scaffold incorporates a reversible albumin-binding motif that extends plasma circulation time and increases cumulative tumor radiation dose, while the Macropa macrocyclic chelator enables stable Actinium-225 complexation at room temperature — a meaningful manufacturing advantage over the conventional DOTA chelator, which requires temperatures above 90°C for adequate Ac-225 labeling. Ratio describes the compound as engineered for high tumor uptake and prolonged retention, with optimized plasma clearance to limit off-target radiation exposure. The ATLAS trial is an open-label Phase I/II study evaluating safety, tolerability, dosimetry, biodistribution, pharmacokinetics, and anti-tumor activity in FAP-expressing soft tissue sarcoma. FAP is a serine protease overexpressed on cancer-associated fibroblasts across multiple solid tumor types, making it an attractive pan-tumor target. Other FAP-directed radiopharmaceuticals in development — including programs using Lu-177 beta-emitting payloads — have generated broad industry interest, but Ratio's use of Actinium-225, an alpha emitter with high linear energy transfer and short path length, is intended to deliver more potent, localized cytotoxicity. The collaboration reflects a broader manufacturing infrastructure challenge specific to alpha-emitting radiopharmaceuticals. Unlike Lu-177-based agents, Actinium-225 programs face constrained isotope supply and require specialized GMP handling, making CDMO network redundancy a clinical-stage priority rather than a commercialization-phase consideration. PharmaLogic is notable as the only cGMP-compliant CDMO currently manufacturing and distributing a commercial radiopharmaceutical therapeutic to more than 30 countries, giving it a credible operational track record for late-stage and commercial-scale alpha therapy supply. Ratio has established a pattern of early partnering across its platform. The company previously entered a research collaboration with Bayer focused on PSMA-targeted radiotherapeutics using its Trillium platform, and partnered with Lantheus on a FAP-targeted PET diagnostic agent that advanced to Phase I imaging study. It also licensed an investigational PET imaging agent to Merck. These deals reflect a platform-first partnering model in which Ratio engages large pharma at the discovery and early clinical stages, retaining its therapeutic pipeline independently. The radiopharmaceutical CDMO sector has seen significant capacity investment as large pharma has moved aggressively into the space. Bristol Myers Squibb's [USD 4.1 billion acquisition of RayzeBio](https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Completes-Acquisition-of-RayzeBio-Adding-Differentiated-Actinium-Based-Radiopharmaceutical-Platform/default.aspx) in early 2024 and Eli Lilly's purchase of Point Biopharma for USD 1.4 billion in 2023 have intensified demand for specialized manufacturing infrastructure, particularly for alpha-emitting programs where production bottlenecks are a known constraint on clinical timelines. --- Spot something wrong? [Report an issue with this article](https://newsgen-prod.reframedata.com/feedback/ratio-therapeutics-manufacturing-collaboration)